Inactive Instrument

Zenyth Therapeutics Limited Stock

Stocks

ZTL

AU000000ZTL7

Pharmaceuticals

End-of-day quote Australian S.E.
- - Intraday chart for Zenyth Therapeutics Limited
Manager TitleAgeSince
Chief Executive Officer - -
Director of Finance/CFO - 2011-02-28
Corporate Officer/Principal - 2011-02-28
Director TitleAgeSince
Director/Board Member - 2011-02-28
Director/Board Member 70 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-0.63%+2.92%+20.84%-7.74% 66.56B
-1.97%-3.45%+49.74%+221.13% 56.51B
-1.13%+40.50%+40.50%+40.50% 42.98B
+1.99%+8.15%-48.83%-54.69% 40.46B
-1.93%-1.97%+63.19%-25.49% 31.91B
+3.64%+17.16%+173.11%-30.97% 31.65B
-1.20%+0.72%+71.67%+83.71% 23.35B
+3.08%+20.43%+4.99%+186.85% 19.46B
+0.21%+3.76%+67.83%+133.69% 17.18B
Average +0.21%+9.08%+49.23%+60.78% 36.67B
Weighted average by Cap. -0.11%+7.69%+43.61%+53.33%
Logo Zenyth Therapeutics Limited
Zenyth Therapeutics, Ltd. develops pharmaceutical and biotechnology products in the therapeutic areas of hematology, bladder cancer and anti-virals. The Company's core business is the research and development medicines to treat human diseases. Zenyth's in-house pharmaceutical R&D is focused on three key areas: infectious diseases, neurological disease, and allergy and inflammation. Its R&D activity targets the clinical development of compounds for serious chronic human diseases.
Employees
-